Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of HSK39297 in anemic PNH patients with persistent anemia despite stable prior C5 antibody therapy
CTR20251209Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ciprocopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Proportion of subjects achieving hemoglobin at least 120 g/L. Started Apr 2025; status: completed.
02
Drugs
ciprocopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20251209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251209.